Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy
Age-related Macular Degeneration

Interventions

DRUG: LFG316
DRUG: Sham
DRUG: LFG316 Lower dose

Sponsor

Novartis Pharmaceuticals